ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Lyn is a SFK with an established role in promoting the survival of imatinib-resistant CML cells from patients and cell lines such as MYL-R independently of BCR-ABL mutations [16], [21]–[23], [25], [68]–[70].